Avian Flu Treatment Global Market Report 2024

Avian flu treatment involves medical approaches and strategies aimed at managing and easing symptoms of avian influenza, commonly known as bird flu, in infected individuals. Avian influenza is caused by viruses that primarily affect birds, though certain strains such as H5N1 and H7N9 can also infect humans, leading to severe illness or even death in some cases.

The primary treatments for avian flu include antibiotics, vaccines, antiviral agents, and immunoglobulins. Antibiotics are medications designed to combat bacterial infections. These treatments are accessible through both online and offline pharmacies and are utilized by various end-users such as hospitals, institutional health centers, and clinics.

The avian flu treatment market research report is one of a series of new reports that provides avian flu treatment market statistics, including avian flu treatment industry global market size, regional shares, competitors with a avian flu treatment market share, detailed avian flu treatment market segments, market trends and opportunities, and any further data you may need to thrive in the avian flu treatment industry. This avian flu treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The avian flu treatment market size has grown strongly in recent years. It will grow from $11.52 billion in 2023 to $12.59 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. During the historical period, growth can be credited to increased demand for avian flu treatments, enhanced measures to prevent bird flu spread, greater availability of treatment options, heightened investments in healthcare infrastructure, and rising demand for poultry consumption.

The avian flu treatment market size is expected to see strong growth in the next few years. It will grow to $18.03 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to heightened awareness and diagnosis, government initiatives aimed at pandemic preparedness, increased investments in research and development, the necessity for effective therapeutics against avian influenza, and extensive research efforts. Key trends anticipated during this period include advancements in therapeutic approaches, ongoing innovation in technologies, collaborative research initiatives, opportunities for new business development and investment, as well as the implementation of telemedicine and remote consultations.

Growing awareness and improved diagnosis are anticipated to drive the expansion of the avian flu treatment market in the future. Awareness involves recognizing a condition, while diagnosis identifies a specific issue based on that awareness. The demand for avian flu treatment stems from the urgent need to protect public health, prevent potential pandemics, and shield poultry populations from substantial economic losses. Awareness and early diagnosis are vital for effective avian flu treatment, enabling prompt intervention and containment to prevent the disease from spreading. For instance, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported in April 2024 that over 8,000 people in the US were under active surveillance from February 9, 2022, to March 29, 2024, after exposure to animals believed to be infected with the HPAI A (H5N1) virus. Thus, increasing awareness and diagnosis are driving the growth of the avian flu treatment market.

Leading companies in the avian flu treatment market are emphasizing partnerships to improve efficacy and accelerate the development of new treatments. These partnerships involve collaborations between pharmaceutical companies, research institutions, and government agencies to pool resources, share expertise, and conduct innovative clinical trials. For example, in April 2024, CureVac N.V., a biotechnology company based in Germany, partnered with GSK plc, a UK-based pharmaceutical company, to develop an investigational influenza A (H5N1) pre-pandemic vaccine candidate. This collaboration aims to address the potential future pandemic threat posed by the H5N1 avian influenza virus by evaluating the safety, reactogenicity, and immunogenicity of the monovalent vaccine candidate, which uses CureVac's proprietary second-generation mRNA technology. The combined Phase 1/2 study will assess the vaccine candidate's safety and effectiveness in healthy adults aged 18 to 64 and older adults aged 65 to 85.

In December 2022, Hester Biosciences Ltd., an Indian animal and poultry vaccine manufacturing company, acquired technology from the Indian Council of Agricultural Research and the National Institute of High-Security Animal Diseases (ICAR-NIHSAD) for an undisclosed amount. This acquisition aims to develop an inactivated H9N2 avian influenza vaccine for poultry, providing a solution to the significant economic losses experienced by Indian poultry farmers due to periodic outbreaks of the disease. The Indian Council of Agricultural Research and the National Institute of High-Security Animal Diseases (ICAR-NIHSAD) is an India-based research institute that offers technology for avian flu vaccines and diagnostic tests for avian influenza.

Major companies operating in the avian flu treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc., Baxter International Inc., CSL Limited, Moderna Inc., Cipla Ltd., Shionogi & Co. Ltd., Novavax Inc., Seqirus Pty Ltd., Sinovac Biotech Ltd., Emergent BioSolutions Inc., Dynavax Technologies Corporation, CureVac AG, Valneva SE, BioCryst Pharmaceuticals Inc., Siga Technologies Inc., Aridis Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., Biolyse Pharma.

North America was the largest region in the avian flu treatment market in 2023. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the avian flu treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the avian flu treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The avian flu treatment market consists of sales of antiviral medications, respiratory support equipment, and intravenous fluids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.